Vaccinex, Inc.

As of November 8, 2021, Vaccinex, Inc. is considered overvalued with negative financial ratios and a significant stock return decline of -87.21%, indicating a deterioration in its financial standing compared to peers like Champions Oncology, Inc. and C4 Therapeutics, Inc.

As of May 1, 2025, the market trend is mildly bearish, supported by bearish daily moving averages and weekly Bollinger Bands, despite some mildly bullish signals from the MACD and a neutral RSI indicating a lack of momentum.

Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing targeted biotherapeutics for serious diseases. As of December 2024, it reported net sales of $0 million and a net loss of $3 million, with a market cap of $1.90 million.

As of Jun 18, Vaccinex, Inc. has a market capitalization of 1.90 million, with net sales of 0.59 million and a net profit of -18.63 million over the last four quarters. The company has shareholder's funds of -2.49 million and total assets of 2.60 million as of Dec 24.